This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Musculoskeletal Conditions
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search
  • X (formerly Twitter) (opens in a new tab)
  • Bluesky (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:25642/feed
ISSN 2327-2236
Infectious Diseases
Vol. 3, Issue 2, 2016October 19, 2015 EDT

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants

Santiago Grau, Carlos Solano, Carol García-Vidal, Isidro Jarque, Jon A. Barrueta, Carmen Peral, Irene Rodríguez, Darío Rubio-Rodríguez, Carlos Rubio-Terrés,
cost-effectiveness analysismicafunginposaconazolevoriconazoleallogeneic hematopoietic stem cell transplantprophylaxisinvasive fungal infections
Copyright Logoccby-4.0 • https://doi.org/10.36469/9832
JHEOR
1.
Grau S, Solano C, García-Vidal C, et al. Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants. JHEOR. 2015;3(2):153-161. doi:10.36469/​9832

View more stats

Powered by Scholastica, the modern academic journal management system